Literature DB >> 20225066

Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2).

Malgorzata Czystowska1, Laura Strauss, Christoph Bergmann, Marta Szajnik, Hannah Rabinowich, Theresa L Whiteside.   

Abstract

Human CD4(+)CD25(high)FOXP3(+) T regulatory cells (Treg) can suppress responder T cell (RC) functions by various mechanisms. In co-cultures of Treg and autologous activated RC, both cell subsets up-regulate the expression of granzymes and perforin, which might contribute to Treg-mediated suppression. Here, we investigate the sensitivity and resistance of Treg and RC to granzyme/perforin-mediated death. CD4(+)CD25(neg) RC were single cell-sorted from the peripheral blood of 25 cancer patients and 15 normal controls. These RC were carboxyfluorescein diacetate succinimidyl ester (CFSE) labeled and co-cultured with autologous CD4(+)CD25(high)FOXP3(+) Treg +/- 150 or +/-1,000 IU/mL of interleukin-2 (IL-2) to evaluate suppression of RC proliferation. In addition, survival of the cells co-cultured for 24 h and 5 days was measured using a flow-based cytotoxicity assay. Freshly isolated Treg and RC expressed granzyme A (GrA), granzyme B (GrB), and perforin. Percentages of positive cells were higher in cancer patients than controls (p < 0.01) and increased upon OKT3 and IL-2 stimulation. Treg, co-cultured with RC at 150 IU/mL of IL-2, no longer expressed cytotoxins and became susceptible to RC-mediated, granzyme/perforin-dependent death. However, in co-cultures with 1,000 IU/mL of IL-2, Treg became resistant to apoptosis and induced GrB-dependent, perforin-independent death of RC. When the GrB inhibitor I or GrB-specific and GrA-specific small inhibitory ribonucleic acids were used to block the granzyme pathway in Treg, RC death, and Treg-mediated suppression of RC, proliferation were significantly inhibited. Human CD4(+)CD25(high) Treg and CD4(+)CD25(neg) RC reciprocally regulate death/growth arrest by differentially utilizing the granzyme-perforin pathway depending on IL-2 concentrations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20225066      PMCID: PMC3777742          DOI: 10.1007/s00109-010-0602-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  32 in total

1.  A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens.

Authors:  A L Givan; J L Fisher; M Waugh; M S Ernstoff; P K Wallace
Journal:  J Immunol Methods       Date:  1999-11-19       Impact factor: 2.303

Review 2.  Unlocking the secrets of cytotoxic granule proteins.

Authors:  M J Smyth; J M Kelly; V R Sutton; J E Davis; K A Browne; T J Sayers; J A Trapani
Journal:  J Leukoc Biol       Date:  2001-07       Impact factor: 4.962

3.  Purification of natural killer cell cytotoxic granules for assaying target cell apoptosis.

Authors:  Joanne E Davis; Vivien R Sutton; Kylie A Browne; Joseph A Trapani
Journal:  J Immunol Methods       Date:  2003-05-01       Impact factor: 2.303

Review 4.  Granzyme B: pro-apoptotic, antiviral and antitumor functions.

Authors:  Joseph A Trapani; Vivien R Sutton
Journal:  Curr Opin Immunol       Date:  2003-10       Impact factor: 7.486

5.  Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection.

Authors:  Marc K Hellerstein; Rebecca A Hoh; Mary Beth Hanley; Denise Cesar; Daniel Lee; Richard A Neese; Joseph M McCune
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 6.  CD4+ CD25+ suppressor T cells: more questions than answers.

Authors:  Ethan M Shevach
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

7.  Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.

Authors:  Magis Mandapathil; Miroslaw J Szczepanski; Marta Szajnik; Jin Ren; Diana E Lenzner; Edwin K Jackson; Elieser Gorelik; Stephan Lang; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

8.  Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells.

Authors:  Wei-Zen Wei; Gerald P Morris; Yi-Chi M Kong
Journal:  Cancer Immunol Immunother       Date:  2003-11-11       Impact factor: 6.968

9.  Killing of target cells by redirected granzyme B in the absence of perforin.

Authors:  Florian C Kurschus; Martin Kleinschmidt; Edward Fellows; Klaus Dornmair; Rainer Rudolph; Hauke Lilie; Dieter E Jenne
Journal:  FEBS Lett       Date:  2004-03-26       Impact factor: 4.124

10.  Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells.

Authors:  Megan K Levings; Romina Sangregorio; Claudia Sartirana; Anna Lisa Moschin; Manuela Battaglia; Paul C Orban; Maria-Grazia Roncarolo
Journal:  J Exp Med       Date:  2002-11-18       Impact factor: 14.307

View more
  19 in total

Review 1.  Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.

Authors:  Magis Mandapathil; Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2011-06-26       Impact factor: 4.388

2.  A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.

Authors:  Theresa L Whiteside; Lisa H Butterfield; Paul H Naylor; James E Egan; John W Hadden; Lorraine Baltzer; Gregory T Wolf; Neil L Berinstein
Journal:  Cancer Immunol Immunother       Date:  2011-11-23       Impact factor: 6.968

3.  Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV.

Authors:  Theresa L Whiteside
Journal:  Cancer Microenviron       Date:  2014-11-12

Review 4.  The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).

Authors:  T L Whiteside; M Mandapathil; P Schuler
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 5.  What are regulatory T cells (Treg) regulating in cancer and why?

Authors:  Theresa L Whiteside
Journal:  Semin Cancer Biol       Date:  2012-03-28       Impact factor: 15.707

6.  Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.

Authors:  Magis Mandapathil; Miroslaw J Szczepanski; Marta Szajnik; Jin Ren; Edwin K Jackson; Jonas T Johnson; Elieser Gorelik; Stephan Lang; Theresa L Whiteside
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

7.  Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Zenichiro Saze; Laura Strauss; Stephan Lang; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

Review 8.  Induced regulatory T cells in inhibitory microenvironments created by cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2014-06-17       Impact factor: 4.388

Review 9.  Induced and natural regulatory T cells in human cancer.

Authors:  Theresa L Whiteside; Patrick Schuler; Bastian Schilling
Journal:  Expert Opin Biol Ther       Date:  2012-07-31       Impact factor: 4.388

10.  Heat shock proteins and regulatory T cells.

Authors:  E W Brenu; D R Staines; L Tajouri; T Huth; K J Ashton; S M Marshall-Gradisnik
Journal:  Autoimmune Dis       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.